Sunshine Biopharma Inc (SBFM)

[pennystockguru2011]

Sunshine Biopharma (OTCBB:SBFM) is looking to fill the gaps in breast cancer therapies with their flagship compound Adva -27, a small molecule that targets and inhibits Top2.

Pre-clinical trials are now behind Sunshine Biopharma with strong data supporting further development of Adva -27. Research to date has shown the compound to be 16-times more effective at killing multi-drug resistant breast cancer cells than Etoposide. Importantly, Adva -27 is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs, and is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates. An excellent pharmacokinetic profile has been generated so far in pre-clinical research as well. Adva -27 has potential for multiple indications, but initial clinical trials will focus on multi-drug resistant breast cancers.